Objective New anti-malarial regimens are urgently needed in sub-Saharan Africa because of the increase in drug resistance. We investigated the safety and efficacy of azithromycin or artesunate combined with sulfadoxine-pyrimethamine used for treatment of malaria in pregnant women in Blantyre, Malawi. Methods/Findings This was a randomized open-label clinical trial, conducted at two rural health centers in Blantyre district, Malawi. A total of 141 pregnant women with uncomplicated Plasmodium falciparum malaria were recruited and randomly allocated to 3 treatment groups: sulfadoxine-pyrimethamine (SP; 3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet); SP plus azithromycin (1 g/day×2 days); or SP plus artesunate (200 mg/day×3 days). Women received two doses administered at least 4 weeks apart. Heteroduplex tracking assays were performed to distinguish recrudescence from new infections. Main outcome measures were incidence of adverse outcomes, parasite and fever clearance times and recrudescence rates. All treatment regimens were well tolerated. Two women vomited soon after ingesting azithromycin. The parasite clearance time was significantly faster in the SP-artesunate group. Recrudescent episodes of malaria were less frequent with SP-azithromycin [Hazard Ratio 0.19 (95% confidence interval 0.06 to 0.63)] and SP-artesunate [Hazard Ratio 0.25 (95% confidence interval 0.10 to 0.65)] compared with SP monotherapy. With one exception (an abortion in the SP-azithromycin group), all adverse pregnancy outcomes could be attributed to known infectious or obstetrical causes. Because of the small sample size, the effect on birth outcomes, maternal malaria or maternal anemia could not be evaluated. Conclusions Both SP-artesunate and SP-azithromycin appeared to be safe, well tolerated and efficacious for the treatment of malaria during pregnancy. A larger study is needed to determine their safety and efficacy in preventing poor birth outcomes. Trial Registration ClinialTrials.gov NCT00287300
References
[1]
World Health Organization (WHO) (2006) World Malaria Report, 2005. Accessed at http://rbm.who.int/wmr2005.
[2]
McGready R, Ashley EA, Moo E, Cho T, Barends M, et al. (2005) A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. The Journal of infectious diseases 192(5): 846–853.
[3]
Brabin BJ (1983) An analysis of malaria in pregnancy in Africa. Bulletin of the World Health Organization 61(6): 1005–1016.
[4]
Guyatt HL, Snow RW (2001) The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. The American Journal of Tropical Medicine and Hygiene 64: (1–2 Suppl)36–44.
[5]
Shulman CE (1999) Malaria in pregnancy: its relevance to safe-motherhood programmes. Annals of Tropical Medicine and Parasitology 93: Suppl 1S59–66.
[6]
World Health Organization (WHO) (2004) Strategic Framework for Malaria Control during Pregnancy in the WHO Africa Region. Accessed at http://rbm.who.int/arusha2002/AFRO_Frame？work_for_Malaria_Control_during_Pregnanc？y_110102.pdf.
[7]
Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, et al. (1999) Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: A randomised placebo-controlled trial. Lancet 353(9153): 632–636.
[8]
van Eijk AM, Ayisi JG, ter Kuile FO, Otieno JA, Misore AO, et al. (2004) Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. Tropical medicine & international health 9(3): 351–360.
[9]
Steketee RW, Wirima JJ, Hightower AW, Slutsker L, Heymann DL, et al. (1996) The effect of malaria and malaria prevention in pregnancy on offspring birthweight, prematurity, and intrauterine growth retardation in rural Malawi. The American Journal of Tropical Medicine and Hygiene 55: (1 Suppl)33–41.
[10]
Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, et al. (1998) Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. The American Journal of Tropical Medicine and Hygiene 59(5): 813–822.
[11]
Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, et al. (2000) Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99. Transactions of the Royal Society of Tropical Medicine and Hygiene 94(5): 549–553.
[12]
Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, et al. (1994) The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. The American Journal of Tropical Medicine and Hygiene 51(5): 515–522.
[13]
Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR (2002) Epidemiology of drug-resistant malaria. Lancet Infectious Diseases 2(4): 209–218.
[14]
Phillips-Howard PA, Wood D (1996) The safety of antimalarial drugs in pregnancy. Drug safety 14(3): 131–145.
[15]
White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, et al. (1999) Averting a malaria disaster. Lancet 353(9168): 1965–1967.
[16]
McGready R, Cho T, Samuel , Villegas L, Brockman A, et al. (2001) Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene 95(6): 651–656.
[17]
Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, et al. (1998) Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clinical infectious diseases 26(1): 146–150.
[18]
Gray RH, Wabwire-Mangen F, Kigozi G, Sewankambo NK, Serwadda D, et al. (2001) Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. American Journal of Obstetrics and Gynecology 185(5): 1209–1217.
[19]
Sarkar M, Woodland CC, Koren G, Einarson AR (2006) Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy and Childbirth 6: 18.
[20]
Malawi National Statistical Office (1998) Malawi Population and Housing Census. Summary of Final Results, Volume 1, Zomba, Malawi 123–126.
[21]
Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, et al. (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354(9181): 795–802.
[22]
Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, et al. (1991) New Ballard Score, expanded to include extremely premature infants. The Journal of pediatrics 119(3): 417–423.
[23]
World Health Organization (WHO) (2005) Susceptibility of Plasmodium falciparum to Antimalarial Drugs. Report on global monitoring 1996-2004. Accessed at http://www.who.int/malaria/includes_en/w？homalariapublications19982004.htm.
[24]
Ngrenngarmlert W, Kwiek JJ, Kamwendo DD, Ritola K, Swanstrom R, et al. (2005) Measuring allelic heterogeneity in Plasmodium falciparum by a Heteroduplex Tracking Assay. The American Journal of Tropical Medicine and Hygiene 72(6): 694–701.
[25]
Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, Silachamroon U, et al. (2005) Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. The Journal of infectious diseases 192(2): 319–322.
[26]
Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, et al. (2007) Estimating True Antimalarial Efficacy by Heteroduplex Tracking Assay in Patients with Complex Plasmodium falciparum Infections. Antimicrobial Agents and Chemotherapy 51(2): 521–7.
[27]
Alker AP, Mwapasa V, Meshnick SR (2004) Rapid real-time PCR genotyping of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy; Antimicrobial Agents and Chemotherapy 48(8): 2924–2929.
[28]
Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. The Journal of infectious diseases 185(3): 380–388.
[29]
Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, et al. (2003) Placental monocyte infiltrates in response to Plasmodium falciparum malaria infection and their association with adverse pregnancy outcomes. The American Journal of Tropical Medicine and Hygiene 68(1): 115–119.
[30]
Therneau T, Grambsch P (2000) Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag.
[31]
Andersen PKCox's regression model for counting processes: A large sample study. Annals of Statistics 10: 1100–1120.
[32]
Wei D (1989) The Robust Inference for the Cox Proportional Hazards Model. Journal of American Statistical Association 84: 1074–1078.
[33]
Bwijo B, Kaneko A, Takechi M, Zungu IL, Moriyama Y, et al. (2003) High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Tropica 85(3): 363–373.
[34]
Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, et al. (2004) Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. British Medical Journal 328(7439): 545.
[35]
Priotto G, Kabakyenga J, Pinoges L, Ruiz A, Eriksson T, et al. (2003) Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: A randomized, double-blind, placebo-controlled trial. Transactions of the Royal Society of Tropical Medicine and Hygiene 97(3): 325–330.
[36]
Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, et al. (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: A longitudinal randomised trial. Lancet, 360(9350): 2031–2038.
[37]
Adam I, Ali DM, Abdalla MA (2006) Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene (7): 632–5.
[38]
Deen JL, von Seidlein L, Pinder M, Walraven GE, Greenwood BM (2001) The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene 95(4): 424–428.
[39]
McGready R, Cho T, Cho JJ, Simpson JA, Luxemburger C, et al. (1998) Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998, 92(4): 430–433.
[40]
McGready R, Cho T, Keo NK, Thwai KL, Villegas L, et al. (2001) Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clinical infectious diseases 33(12): 2009–2016.
[41]
Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. (2005) Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: A randomised trial. Lancet 365(9469): 1467–1473.
[42]
Clark RL, White TE, Clode S, Gaunt I, Winstanley P, et al. (2004) Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71(6): 380–394.
[43]
World Health Organization (WHO) (1996) Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated malaria in areas with intense transmission.
[44]
Adair CD, Gunter M, Stovall TG, McElroy G, Veille JC, et al. (1998) Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin. Obstetrics and Gynecology 91(2): 165–168.
[45]
Hastings IM, Ward SA (2005) Coartem (artemether-lumefantrine) in Africa: The beginning of the end? The Journal of infectious diseases 192(7): 1303–1304.
[46]
ter Kuile FO, Parise ME, Verhoeff FH, Udhayakumar V, Newman RD, et al. (2004) The burden of co-infection with Human Immunodeficiency Virus type 1 and malaria in pregnant women in sub-Saharan Africa. The American Journal of Tropical Medicine and Hygiene 71: (2 Suppl)41–54.
[47]
Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, et al. (2005) Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrobial Agents and Chemotherapy 49(9): 3919–3921.
[48]
Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, et al. (2006) Randomized Trial of 2-Dose versus Monthly Sulfadoxine-Pyrimethamine Intermittent Preventive Treatment for Malaria in HIV-Positive and HIV-Negative Pregnant Women in Malawi. The Journal of infectious diseases 194(3): 286–293.
[49]
Brentlinger PE, Behrens CB, Micek MA (2006) Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infectious Diseases 6(2): 100–111.
